|
Gene: ERV3-1 |
Gene summary for ERV3-1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ERV3-1 | Gene ID | 2086 |
Gene name | endogenous retrovirus group 3 member 1, envelope | |
Gene Alias | ERV-R | |
Cytomap | 7q11.21 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q14264 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2086 | ERV3-1 | LZE2D | Human | Esophagus | HGIN | 1.01e-02 | 7.49e-01 | 0.0642 |
2086 | ERV3-1 | LZE4T | Human | Esophagus | ESCC | 6.99e-07 | 1.87e-01 | 0.0811 |
2086 | ERV3-1 | LZE7T | Human | Esophagus | ESCC | 1.02e-06 | 2.85e-01 | 0.0667 |
2086 | ERV3-1 | LZE20T | Human | Esophagus | ESCC | 2.32e-07 | 2.65e-01 | 0.0662 |
2086 | ERV3-1 | LZE22T | Human | Esophagus | ESCC | 1.07e-04 | 4.50e-01 | 0.068 |
2086 | ERV3-1 | LZE24T | Human | Esophagus | ESCC | 7.69e-17 | 4.57e-01 | 0.0596 |
2086 | ERV3-1 | LZE6T | Human | Esophagus | ESCC | 4.03e-07 | 3.09e-01 | 0.0845 |
2086 | ERV3-1 | P1T-E | Human | Esophagus | ESCC | 8.97e-28 | 1.17e+00 | 0.0875 |
2086 | ERV3-1 | P2T-E | Human | Esophagus | ESCC | 1.75e-25 | 4.18e-01 | 0.1177 |
2086 | ERV3-1 | P4T-E | Human | Esophagus | ESCC | 1.07e-19 | 4.65e-01 | 0.1323 |
2086 | ERV3-1 | P5T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.84e-01 | 0.1327 |
2086 | ERV3-1 | P8T-E | Human | Esophagus | ESCC | 5.79e-16 | 3.24e-01 | 0.0889 |
2086 | ERV3-1 | P9T-E | Human | Esophagus | ESCC | 7.41e-15 | 3.51e-01 | 0.1131 |
2086 | ERV3-1 | P10T-E | Human | Esophagus | ESCC | 3.96e-39 | 5.93e-01 | 0.116 |
2086 | ERV3-1 | P11T-E | Human | Esophagus | ESCC | 1.17e-09 | 3.46e-01 | 0.1426 |
2086 | ERV3-1 | P12T-E | Human | Esophagus | ESCC | 2.27e-21 | 3.86e-01 | 0.1122 |
2086 | ERV3-1 | P15T-E | Human | Esophagus | ESCC | 2.96e-12 | 2.58e-01 | 0.1149 |
2086 | ERV3-1 | P16T-E | Human | Esophagus | ESCC | 1.47e-14 | 2.57e-01 | 0.1153 |
2086 | ERV3-1 | P19T-E | Human | Esophagus | ESCC | 3.93e-02 | 3.59e-01 | 0.1662 |
2086 | ERV3-1 | P20T-E | Human | Esophagus | ESCC | 1.66e-19 | 4.37e-01 | 0.1124 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERV3-1 | SNV | Missense_Mutation | rs200537808 | c.1615N>A | p.Gln539Lys | p.Q539K | Q14264 | protein_coding | deleterious(0.05) | benign(0.106) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
ERV3-1 | SNV | Missense_Mutation | rs377605592 | c.403G>A | p.Val135Ile | p.V135I | Q14264 | protein_coding | tolerated(0.33) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ERV3-1 | SNV | Missense_Mutation | c.1310G>A | p.Cys437Tyr | p.C437Y | Q14264 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
ERV3-1 | SNV | Missense_Mutation | novel | c.1609N>C | p.Ala537Pro | p.A537P | Q14264 | protein_coding | deleterious(0.01) | possibly_damaging(0.537) | TCGA-BH-A1FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ERV3-1 | SNV | Missense_Mutation | rs762732410 | c.227G>A | p.Gly76Asp | p.G76D | Q14264 | protein_coding | tolerated(0.49) | benign(0.012) | TCGA-C8-A12U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ERV3-1 | SNV | Missense_Mutation | rs200537808 | c.1615N>A | p.Gln539Lys | p.Q539K | Q14264 | protein_coding | deleterious(0.05) | benign(0.106) | TCGA-EW-A1J6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
ERV3-1 | insertion | Nonsense_Mutation | novel | c.1079_1080insCAGATGATTCTTCTGCTTCAGTCTCCTGAGTAGCTGGGATC | p.Leu360PhefsTer3 | p.L360Ffs*3 | Q14264 | protein_coding | TCGA-A8-A07P-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
ERV3-1 | insertion | In_Frame_Ins | novel | c.776_777insATATTGTTGTCCTAG | p.Glu259_His260insTyrCysCysProArg | p.E259_H260insYCCPR | Q14264 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ERV3-1 | deletion | In_Frame_Del | c.74_88delGGGAGGGATGCCTCC | p.Trp25_His30delinsTyr | p.W25_H30delinsY | Q14264 | protein_coding | TCGA-E9-A22G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |||
ERV3-1 | SNV | Missense_Mutation | rs200537808 | c.1615N>A | p.Gln539Lys | p.Q539K | Q14264 | protein_coding | deleterious(0.05) | benign(0.106) | TCGA-C5-A8YT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |